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Background: Clinicians often apply heating or cooling stimulation for treatment of musculoskeletal pain. However,
scalding, frostbite and skin ulcers may occur from the excessive use of either therapy alone. Heating and cooling
combination therapy may be a suitable alternative for treatment of musculoskeletal diseases, although insufficient
research has documented the safety and efficacy of such therapy. The purpose of this clinical trial is to determine
the efficacy and safety of heating and cooling combination therapy for treatment of chronic low back pain.
Methods/Design: This is a multicenter, parallel-group, double-blinded, randomized controlled trial to evaluate the
efficacy and safety of a heating and cooling combination therapeutic device (OCH-S100) in patients with chronic
low back pain. Eighty participants with chronic low back pain will be recruited from two hospitals in South Korea
(Dongguk University Ilsan Oriental Hospital and Dongguk University Bundang Oriental Hospital). Enrolled patients
will be randomly divided into a treatment group and a sham group. Patients in both groups will be given 10 treatments
(15 min per treatment) over 4 weeks. The protocol will consist of five cycles of heating/cooling therapy
(maximum: 45 °C, minimum: 15 °C) in the treatment group, and five cycles of sham therapy (maximum: 1 °C above
skin temperature, minimum: 1 °C below skin temperature) in the sham group. The primary outcome measure is
change from baseline in the 100 mm Visual Analogue Scale (VAS) for pain after 4 weeks. There are six secondary
outcome measures that consider disability or range of motion (ROM).
Discussion: This research will determine the efficacy and safety of heating and cooling combination therapy on
chronic low back pain. The results of this trial may have important implications for the more widespread use of
heating and cooling combination therapy for treatment of musculoskeletal pain.
Trial Registration: NCT02289170 (14 October 2014)
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Heating and cooling therapies are widely used to treat
musculoskeletal pain [1]. For example, in the United
States, 75 % of patients with low back pain are treated
with heating therapy and 7 % with cooling therapy [2].
Heating therapy increases tissue temperature, blood
flow, metabolism and connective tissue extensibility [1].
There are also reports that heating therapy increases the
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creativecommons.org/publicdomain/zero/1.0/decreases the activity of most group II spindle afferents,
decreases muscle spasms, and increases the speed of
nerve conduction [3]. Other studies indicated that heat-
ing therapy is more effective than placebo in relieving
pain, decreasing disability, decreasing muscle tension,
and improving range of motion [4, 5].
There is evidence that cooling therapy decreases tissue
blood flow due to vasoconstriction, and that it also
reduces tissue metabolism, oxygen utilization, and in-
flammation [1, 6]. Cooling therapy decreases the velocity
of nerve conduction in superficial tissues by slowing the
firing of muscle spindle afferents and reflex responses,
thus decreasing muscle spasms and pain [7]. Use ofle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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reduce intake of painkillers because it reduces pain and
body fluid penetration [8].
However, the overuse of cooling therapy or heating
therapy due to physiological adaptation can lead to skin
damage such as scalding, frostbite, and ulcers [1, 6]. We
developed a heating and cooling combination therapy
device (OCH-S00) that reduces the probability of skin
damage. This device maximizes the stimulation and
reduces the potential harm from heating and cooling by
use of a probe to reduce sensory adaptation.
Thermo-receptors are sensitive to different tempera-
tures. Thus, TRPA1 is mainly responsible for painful
cold sensation below 18 °C, TRPM8 for cool sensation at
23 to 28 °C, TRPV2 for warm sensation at 30 to 39 °C,
and TRPV1 for painful hot sensation above 43 °C [9].
The heating and cooling device described here stimu-
lates the cold, cool, warm and hot receptors by applying
temperatures in the range of 15 to 45 °C, well below the
burn point. Thus, this device is expected to have anti-
inflammatory effects, increase muscle relaxation, de-
crease edema and provide pain relief, without damaging
the skin.
The purpose of this research is to evaluate the safety
and efficacy of the OCH-S100 heating and cooling com-




This research of the clinical efficacy and safety of heat-
ing and cooling combination therapy is a multicenter,
randomized, double-blinded, parallel-group study. All
enrolled subjects are patients with chronic low back pain.
This research protocol was externally peer reviewed by
Korean Ministry of Food and Drug Safety (KMFDS) and
Korean Health Industry Development Institute (KHIDI).
Two clinical research centers in Korea will participate in
this trial: Dongguk University Ilsan Oriental Hospital and
Dongguk University Bundang Oriental Hospital. This re-
search protocol was approved by Dongguk University
Ilsan Oriental Hospital’s Institutional Review board (IRB)
and Dongguk University Bundang Oriental Hospital’s
IRB. Each subject will provide informed consent before
enrollment.
Recruitment
Participants will be recruited through advertisements
in local newspapers and on bulletin boards at each
trial center. The target sample size is 80 subjects.
Telephone screening will be performed before the
trial to determine if subjects fulfill the selection cri-
teria. Final enrollment will be determined by an
orthopedist and a radiologist through physical exams,radiological tests, blood and urine tests, and relevant
questionnaires.
Participants
All outpatients who are 20 to 75 years of age and have
suffered from low back pain in the previous 3 months or
more and had ratings over 40 mm on a 100 mm Visual
Analog Scale (VAS) for pain will be screened. Subjects
will be excluded if any of the following are present:
(i) trauma or surgery in the lumbar region in the
6 months prior to enrollment; (ii) low back pain accom-
panied by sciatica; (iii) systemic disease or severe
dysfunction due to another medical problem (cancer,
infection, etcetera); (iv) history of using medication(s),
traditional oriental medical care, or physiotherapy for
treatment of low back pain in the 4 weeks prior to en-
rollment; (v) neurological disease, such as topical or
whole body hypoesthesia, that may affect temperature
sensation (stroke, peripheral neuropathy, etcetera);
(vi) hypersensitivity to heating and cooling stimulation;
(vii) pregnancy or lactating; or (viii) participation in other
clinical trials in the 3 months prior to or after enrolling
in this trial.
Randomization and blinding
Randomization will be performed by an independent
statistician using a computerized random-number gener-
ator through the block-randomization method of SAS
version 9.1 (SAS Institute Inc. Cary, NC, USA). Separate
randomization files will be created for each study site.
Allocation concealment will be maintained by use of
opaque sealed envelopes. After the researcher screens a
patient for inclusion and receives signed informed con-
sent, the next envelope in the sequence will be accessed
and opened by the certified Korean Medicine Doctor
who supervises the medical device, immediately prior to
treatment. A total of 80 participants will be randomly
and blindly assigned to a treatment group or a sham
group. All subjects, practitioners, and the outcome as-
sessor will be blinded to group assignment. Blinding of
the certified Korean Medicine Doctor who supervises
the medical device and sets up the treatment (medical
equipment manager) is not possible. The patients will be
told: “You will be treated with one of two heating and
cooling combination treatments. One has a large range
of temperature change and the other has a small range
of temperature change.”
Treatment and assessment
Subjects in both groups will be treated 10 times over
4 weeks. The treatment term of 4 weeks was based on
previous studies of the treatment of general chronic low
back pain [10]. Each treatment will be 15 min and there
will be two to three treatments per week, based on the
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combination treatment [11]. The outcome assessor (who
does not participate in the treatment) will measure the
degree of pain sensitivity by pressing eight acupoints
(four on each side of the waist; BL23, BL24, BL25, and
BL26) that are frequently used to assess low back pain
[12–16]. This assessment will employ a pressure alg-
ometer, with a circular and flat probe of 1 cm diameter
(Commander Algometer, JTECH Medical, Midvale,
Utah, USA), to identify the two most painful acupoints.
Before treatment, the medical equipment manager will
measure the skin temperature of each patient in the
treatment and sham groups using thermometer (Superfast
Thermapen Pro-surface, ETI, England) (Table 1).
Heating and cooling combination therapy
The patients in this group will receive heating and cool-
ing combination therapy. The probe is attached to the
acupuncture points for 15 min, and its temperature will
be cycled five times, from the maximum of 45 °C to the
minimum of 15 °C. This temperature range was chosen
to provide stimulation of cold, cool, warm and hot
receptors.
Sham therapy
The patients in this group will receive sham heating and
cooling combination therapy under identical conditions,
except for probe temperature. The probe’s temperature
will be cycled five times, from 1 °C above skin tem-
perature to 1 °C below skin temperature.
During the 4-week study, patients will be prohibited
from using any treatment that could influence the re-
sults, such as analgesics, nonsteroidal anti-inflammatory
drugs, muscle relaxants, oral corticosteroids, antidepres-
sants, steroid injections, high frequency heat coagulation,
physiotherapy, acupuncture, moxibustion and surgery.Table 1 Content of outcome measurement
Treatment Number
Outcome measure B 1 2 3 4 5 6 7 8 9 10 F
Primary outcome
VAS X X X X X X X X X X X X
Secondary outcomes
KODI X X X X
KRMDQ X X X X
TMBQ X X X X
Modified Schöber test X X X X
Finger-to-floor distance X X X X
Finger-to thigh distance X X X X
B baseline, F follow-up, VAS Visual Analog Scale, KODI Korean Oswestry disability
index, KRMDQ Korean Roland Morris Disability Questionnaire, TMBQ Traditional
Medicine Back pain QuestionnairePatients who use any of these treatments will be excluded.
All patients will be questioned about medication usage
during each treatment session.
Quality assurance
We will educate all practitioners and set qualification
standards to make sure the patients are treated with high
standards and in accordance with the trial protocol.
Treatment will be administered by doctors of Korean
Medicine who have extensive clinical experience with
heating and cooling stimulation therapy and moxi-
bustion and the following qualifications: (i) graduate
of a 6-year full-time course in Korean Medicine,
taught as a college program; (ii) certified by the Korean
Ministry of Health and Welfare as a Korean Medicine
Doctor; (iii) more than 1 year of postgraduate clinical
training in an Oriental medicine hospital; and (iv) comple-
tion of the first-year residency program in our Department
of Acupuncture and Moxibustion.
Practitioners and medical equipment managers will at-
tend a 2-day training workshop about the treatment pro-
grams and will be educated on selection of acupoints by
using a pressure algometer. Medical equipment managers
will also be educated on measuring skin temperature and
setting the treatment and sham devices. A written
protocol and standardized recording documents will be
provided. Because the relationship between a practi-
tioner and patient could influence the results, all such
interactions will be strictly limited, except when report-
ing side effects. All practitioners and outcome assessors
will be blinded to group allocations, and medical equip-
ment managers will not participate in the interventions.
To assure blinding of patients, we will put a small fab-
ric curtain next to the device to block the patient’s
view.
Analysis of data
A VAS will be used to assess the effect of treatment. The
primary endpoint is the change in the 100 mm Pain VAS
from baseline (before treatment) to 4 weeks [10, 12, 17].
The 100 mm VAS is widely used because it provides reli-
able and valid measurements of pain intensity [18]. Each
patient will be asked to check their pain intensity along an
ungraded 100 mm horizontal line, where ‘0’ represents ‘no
pain’ and ‘100’ represents ‘unbearable pain’.
The secondary endpoints are change from baseline
in three evaluations of functional disability (Korean
Oswestry disability index [KODI], Korean Roland Morris
Disability Questionnaire [KRMDQ], and Traditional
Medicine Back pain Questionnaire [TMBQ]) and three
evaluations of range of motion (ROM) (modified Schöber
test, finger-to-floor distance, and finger-to-thigh distance).
These parameters will be measured at baseline, 2 weeks,
4 weeks, and at 4 weeks after the last treatment.
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ities and each item has six possible responses, ranging
from ‘no problem’ to ‘not possible’. The KODI focuses
on a limitation in the range of physical functions, includ-
ing standing, walking, lifting, sitting, lying down, dress-
ing, and personal care [18]. We excluded questions
about sexual activities because many subjects do not
provide honest answers about their sex lives, and it is
hard to account for subjects who are single. The
KRMDQ contains 24 yes/no queries and also focuses on
limitations in physical functions, including walking,
bending over, sitting, lying down, dressing, sleeping, self-
care, and daily activities. The KRMDQ is easy to under-
stand, interpret and score. Higher scores in the KRMDQ
and KODI indicate greater disability [18]. We will use
Korean versions of these surveys, which have docu-
mented reliability and validity [19, 20]. The TMBQ eval-
uates low back pain and is based on traditional Korean
medicine [21].
The modified Schöber test measures the curvature of
the spine. In this test, the lumbosacral junction is
marked on the back; a second mark is placed 5 cm
below the junction, and a third mark is placed 10 cm
above the junction. Then the subject is asked to bend
forward as far as possible, and the new distance between
the second and third marks is measured [22]. We will
also use a digital flexibility testing device (Standing
Trunk Flexion meter TKK5403, Takei Co., Japan) to
assess the trunk flexibility, finger-to-floor distance
(distance between the fingertips and the floor after forward
flexion with knees straight, while on a 20-cm high box)
[23], and finger-to-thigh distance (distance between the
fingertips and the floor after lateral bending with knees
straight, while on a 20-cm high box) [24].
Safety assessments
Any physical or clinical changes will be reported by the
assessor, practitioner, and patient at each visit. All symp-
toms, date of onset, and duration will be recorded.
Sample size
The primary endpoint will be change in 100 mm VAS
score after 4 weeks of treatment. Liu et al. [25] previ-
ously showed that the 4-week change was 7.6 for the test
device and 3.9 for the control device. Patients will be
randomized to the test and sham groups in a 1:1 ratio.
Assuming a reference standard deviation (SD) of 5.37,
power analysis indicates that a sample size of 34 has an
80 % probability of yielding a significant difference at the
level of 0.05. In order to achieve stronger results, a one-
sided 97.5 % lower confidence limit for the treatment
difference (VAS on test device - VAS on sham device)
will be greater than 0. We will allow for a 15 % dropout
rate by randomization of 40 subjects to each group.Statistical analysis
All data will be analyzed using SAS version 9.1 (SAS
institute Inc. Cary, NC, USA). All statistical tests will
be two-sided, and the level of significance will be set
at 0.05. Continuous variables will be expressed as
means ± SDs and categorical variables as numbers and
percentages. For analysis of the primary endpoint, the
two-sided 95 % confidence interval will calculated by
analysis of covariance (ANCOVA) and the model will in-
clude fixed-effect for study site. Student’s t-test will be
used for evaluation of primary and secondary end-points.
Categorical data will be analyzed using Pearson’s chi-
square test or Fisher’s exact test, as appropriate.
For safety analysis, the numbers and percentages of
patients will be presented in a frequency table. Patients
with adverse events will be listed along with their med-
ical histories and concomitant medications, with start
and stop dates. Categorical variables will be summarized
by frequency tables, and continuous laboratory variables,
and changes from baseline will be expressed by sum-
mary statistics. In addition, the number and percentage
of patients with each value below, within and above
the normal range will be tabulated, and “shift tables”
(summaries of individual changes in laboratory pa-
rameters) will be generated.
Discussion
This clinical research aims to evaluate the safety and
efficacy of OCH-S100, a device designed to administer
heating and cooling combination therapy and provide
relief for patients with chronic low back pain.
Heating and cooling therapy is widely used for treat-
ment of musculoskeletal pain in clinical practice [7, 11].
The beneficial effects of this therapy may be medi-
ated by changing blood flow, decreasing inflamma-
tion, induction of contraction and relaxation of blood
vessels, decreasing edema, or decreasing stiffness of
the muscle [11], but the underlying mechanism has
not yet been proven. Moreover, there is only limited
research on the efficacy of heating and cooling com-
bination therapy. Thus, the clinical research described
here is one of the few studies to test rigorously the effi-
cacy and safety of heating and cooling combination
therapy. Our research was designed to be rigorous, in
that it will employ two study centers, double blinding
of all assessors and practitioners, prior education of all
practitioners, and fabric curtains to block patients’ view
of the device. Moreover, a certified Korean Medicine
Doctor with extensive experience will be treating all
patients.
The device used in this research can precisely deliver
temperatures from 15 °C to 45 °C, temperatures that do
not burn or damage the skin. Therefore, this research
will be able to document the effect of stimulation of the
Kim et al. Trials  (2015) 16:285 Page 5 of 5cold, cool, warm, and hot receptors on patients with
chronic low back pain.
Trial status
Patient recruitment is ongoing. Enrollment and trial
completion is expected by the end of 2015.
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